Related Experiment Video

Updated: Jun 6, 2025

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

6.8K

Rapidly Progressive Idiopathic Pyoderma Gangrenosum in a Pediatric Patient Successfully Treated With Infliximab

Nikhita J Perry1, Stephanie Wang1, Robert Smith2

  • 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Pediatric Dermatology
|November 25, 2024
PubMed

Insights

Pyoderma gangrenosum (PG) is a rare pediatric skin condition. This case highlights the need for multi-modal therapy beyond corticosteroids for rapidly progressive cases in children.

Area of Science:

  • Dermatology
  • Pediatric Medicine
  • Immunology

Background:

  • Pyoderma gangrenosum (PG) is a rare, ulcerative skin disease with unknown causes.
  • Pediatric cases of PG are infrequent, representing about 4% of all patients.
  • Standard treatment involves topical and systemic corticosteroids, often leading to quick symptom relief.

Observation:

  • This report details a rare case of rapidly progressing pediatric pyoderma gangrenosum.
  • The inciting cause of the condition was unknown.
  • The patient was an infant or child.

Findings:

  • Initial treatment with corticosteroids proved insufficient for this rapidly progressive case.
  • A multi-modal therapeutic approach was required.
  • The treatment regimen included systemic and topical corticosteroids, high-dose infliximab, and colchicine.

Implications:

  • This case underscores the potential need for advanced therapies in severe pediatric PG.
  • Understanding the pathophysiology of pediatric PG may lead to more targeted treatments.
  • Aggressive management strategies may be necessary for refractory or rapidly progressing pediatric skin disorders like PG.

Keywords:
infliximabneutrophilic dermatosispediatric pyoderma gangrenosum

More Related Videos

Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis04:01

Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis

Published on: September 8, 2022

2.4K
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

15.9K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
113
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
185